Genfit: New Phase I Clinical Trials With High-Dose Confirm The Excellent Tolerance Of GFT505 In Healthy Volunteers
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announced the first data of a new Phase I clinical trials of
Posted: November 20th, 2008 under Health.
Tags: Health, the